These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 32805517

  • 1. Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes.
    Blanton KC, Deal AM, Kaiser-Rogers KA, Anders CK, O'Connor SM, Hertel JD, Calhoun BC.
    Ann Diagn Pathol; 2020 Oct; 48():151576. PubMed ID: 32805517
    [Abstract] [Full Text] [Related]

  • 2. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR, Shetty S, Wang Z, Rivera CL, Portier BP, Budd GT, Downs-Kelly E, Lanigan CP, Calhoun BC.
    Cancer; 2017 Jun 15; 123(12):2230-2239. PubMed ID: 28192599
    [Abstract] [Full Text] [Related]

  • 3. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K, Tantravahi U, Lomme MM, Pasquariello T, Steinhoff M, Sung CJ.
    Breast Cancer Res Treat; 2016 Jun 15; 157(3):405-11. PubMed ID: 27180259
    [Abstract] [Full Text] [Related]

  • 4. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
    Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ.
    JAMA Oncol; 2019 Mar 01; 5(3):366-375. PubMed ID: 30520947
    [Abstract] [Full Text] [Related]

  • 5. Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe.
    Zare S, Lin L, Alghamdi AG, Daehne S, Roma AA, Hasteh F, Dell'Aquila M, Fadare O.
    Am J Surg Pathol; 2018 Sep 01; 42(9):1208-1215. PubMed ID: 29923906
    [Abstract] [Full Text] [Related]

  • 6. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY.
    Hum Pathol; 2020 Apr 01; 98():10-21. PubMed ID: 32027910
    [Abstract] [Full Text] [Related]

  • 7. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
    Ragazzi M, Bisagni A, Gasparini E, Kuhn E, Bassano C, Tamagnini I, Foroni M, Bortesi M, Falco G, Ferrari G, Braglia L, Savoldi L, Bologna A, Di Cicilia R, Bisagni G, Gardini G.
    Breast; 2017 Aug 01; 34():65-72. PubMed ID: 28521178
    [Abstract] [Full Text] [Related]

  • 8. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
    Jang MH, Kim EJ, Kim HJ, Chung YR, Park SY.
    Breast Cancer Res Treat; 2015 Aug 01; 153(1):67-77. PubMed ID: 26223814
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines.
    Yang L, Chen M, Pu T, Wu S, Wei B, Yang J, Bu H, Zhang Z.
    J Clin Pathol; 2020 May 01; 73(5):283-290. PubMed ID: 31732618
    [Abstract] [Full Text] [Related]

  • 11. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS, Bowman AS, Zehir A, Razavi P, Brogi E, Ladanyi M, Arcila ME, Wen HY, Ross DS.
    Histopathology; 2021 Mar 01; 78(4):498-507. PubMed ID: 32841416
    [Abstract] [Full Text] [Related]

  • 12. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
    Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown AM.
    J Clin Oncol; 2011 Nov 01; 29(31):4168-74. PubMed ID: 21947821
    [Abstract] [Full Text] [Related]

  • 13. Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort.
    Zare S, Rong J, Daehne S, Roma A, Hasteh F, Dell'Aquila M, Fadare O.
    Mod Pathol; 2019 Nov 01; 32(11):1566-1573. PubMed ID: 31190000
    [Abstract] [Full Text] [Related]

  • 14. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, Ikpatt OF, Gomez C, Zhao W, Reis IM.
    Breast Cancer Res Treat; 2016 Feb 01; 155(3):457-62. PubMed ID: 26895325
    [Abstract] [Full Text] [Related]

  • 15. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features.
    Zare SY, Lin L, Alghamdi AG, Daehne S, Roma AA, Hasteh F, Dell'Aquila M, Fadare O.
    Hum Pathol; 2019 Jan 01; 83():7-13. PubMed ID: 30121371
    [Abstract] [Full Text] [Related]

  • 16. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH, Lim AS, Thike AA, Tien SL, Tan PH.
    Arch Pathol Lab Med; 2016 Feb 01; 140(2):140-7. PubMed ID: 26910218
    [Abstract] [Full Text] [Related]

  • 17. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
    Solomon JP, Dell'Aquila M, Fadare O, Hasteh F.
    Am J Clin Pathol; 2017 Apr 01; 147(4):432-437. PubMed ID: 28340220
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, Rayson D, Younis T, Thompson K, Barnes PJ.
    Histopathology; 2015 Dec 01; 67(6):880-7. PubMed ID: 25913507
    [Abstract] [Full Text] [Related]

  • 20. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
    Davies V, Voutsadakis IA.
    Cancer Invest; 2020 Feb 01; 38(2):94-101. PubMed ID: 31977265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.